Biomarkers of Macrophage Activation and Immune Danger Signals Predict Clinical Outcomes in Alcoholic Hepatitis
Banishree Saha(University of Massachusetts Chan Medical School), Gyöngyi Szabó(Beth Israel Deaconess Medical Center), Mack C. Mitchell(Southwestern Medical Center), Svetlana Radaeva(National Institute on Alcohol Abuse and Alcoholism), Craig J. McClain(University of Louisville), Aimee Kroll‐Desrosiers(University of Massachusetts Chan Medical School), Dávid Tornai(Beth Israel Deaconess Medical Center), Patrick Lowe(University of Massachusetts Chan Medical School), Arthur J. McCullough(Cleveland Clinic), Adeyinka Adejumo(University of Massachusetts Chan Medical School), Karen Kodys(University of Massachusetts Chan Medical School), Bruce Barton(University of Massachusetts Chan Medical School), Srinivasan Dasarathy(Cleveland Clinic)
Cited by 77
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
|New England Journal of Medicine|2021|1.1k
Endpoints and clinical trial design for nonalcoholic steatohepatitis
|Hepatology|2011|757